Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137488
Status:
COMPLETED
Last Update Posted:
2016-02-26
First Post:
2005-08-26
Brief Title:
Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma LGG
Sponsor:
AHS Cancer Control Alberta
Organization:
AHS Cancer Control Alberta
Study Overview
Official Title:
Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma LGG
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The low grade glioma LGG is a type of brain tumor which is generally more common in younger age group patients Most patients with LGG undergo surgery which is mostly incomplete due to concern about loss of function This is an incurable disease More than half of these patients progress to a higher grade with a worse outcome within five years of their diagnosis and only one-third survive for up to ten years Post-operative radiation treatment improves local control without survival advantage Efforts are being made without great success to select the patients with a higher risk of progression based on physical characteristics and histological features
Tumor vascularity is thought to be the key element in tumor progression Tremendous progress has been made in functional imaging by using magnetic resonance imaging MRI 3-Tesla 3T and in biotechnology which can be used to investigate angiogenic gene profiles in order to identify gene signature for these tumors In this study the investigators are proposing that patients of LGG with a higher risk of tumor progression may be selected by functional imaging and angiogenic profiles These higher risk patients may be candidates for post-operative radiation in the future with a potential survival benefit
Tumor vascularity is thought to be the key element in tumor progression Tremendous progress has been made in functional imaging by using magnetic resonance imaging MRI 3-Tesla 3T and in biotechnology which can be used to investigate angiogenic gene profiles in order to identify gene signature for these tumors In this study the investigators are proposing that patients of LGG with a higher risk of tumor progression may be selected by functional imaging and angiogenic profiles These higher risk patients may be candidates for post-operative radiation in the future with a potential survival benefit
Detailed Description:
Summary Comprehensive analysis of the angiogenesis-related gene expression profiles and tumor perfusion of patients with LGG will provide a novel understanding of subgroup low and high-risk of LGG Thus this study will allow identifying clinically relevant factors predictive for tumor progression and to select patients in high-risk group for adjuvant radiation therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None